These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33840795)

  • 1. Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study.
    Catalán-Latorre A; Sureda M; Brugarolas-Masllorens A; Escudero-Ortiz V
    Ther Drug Monit; 2021 Aug; 43(4):447-450. PubMed ID: 33840795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    Miyamoto S; Azuma K; Ishii H; Bessho A; Hosokawa S; Fukamatsu N; Kunitoh H; Ishii M; Tanaka H; Aono H; Nakahara Y; Kusaka K; Hosomi Y; Kikuchi N; Mori Y; Itani H; Hamada A; Yamada K; Okamoto H
    JAMA Oncol; 2020 Jul; 6(7):e201250. PubMed ID: 32407455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
    Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
    van Leeuwen RW; Peric R; Hussaarts KG; Kienhuis E; IJzerman NS; de Bruijn P; van der Leest C; Codrington H; Kloover JS; van der Holt B; Aerts JG; van Gelder T; Mathijssen RH
    J Clin Oncol; 2016 Apr; 34(12):1309-14. PubMed ID: 26858332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
    Fukudo M; Ikemi Y; Togashi Y; Masago K; Kim YH; Mio T; Terada T; Teramukai S; Mishima M; Inui K; Katsura T
    Clin Pharmacokinet; 2013 Jul; 52(7):593-609. PubMed ID: 23532985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
    Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
    Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.
    Mazzoni F; Rotella V; Pratesi N; Boni L; Simi L; Orlando C; Comin CE; Maddau C; Di Costanzo F
    Tumori; 2011; 97(2):160-5. PubMed ID: 21617709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung Cancer.
    Aren O; Samtani S; Frelinghuysen M; Burotto M
    Am J Ther; 2021 Jul-Aug 01; 28(4):e375-e379. PubMed ID: 31567201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
    Smit EF; Wu YL; Gervais R; Zhou C; Felip E; Feng J; Guclu SZ; Hoiczyk M; Dorokhova E; Freudensprung U; Grange S; Perez-Moreno PD; Mitchell L; Reck M
    Lung Cancer; 2016 Sep; 99():94-101. PubMed ID: 27565921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
    Sorensen BS; Wu L; Wei W; Tsai J; Weber B; Nexo E; Meldgaard P
    Cancer; 2014 Dec; 120(24):3896-901. PubMed ID: 25103305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
    Svedberg A; Vikingsson S; Vikström A; Hornstra N; Kentson M; Branden E; Koyi H; Bergman B; Gréen H
    Br J Clin Pharmacol; 2019 Aug; 85(8):1704-1709. PubMed ID: 30945322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.
    Lankheet NA; Schaake EE; Burgers SA; van Pel R; Beijnen JH; Huitema AD; Klomp H;
    Clin Lung Cancer; 2015 Jul; 16(4):320-4. PubMed ID: 25682545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
    Lee VW; Schwander B; Lee VH
    Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
    Brueckl WM; Achenbach HJ; Ficker JH; Schuette W
    BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib in non-small-cell lung cancer.
    Gridelli C; Rossi A; Maione P; Colantuoni G; Del Gaizo F; Ferrara C; Nicolella D; Guerriero C
    Expert Opin Pharmacother; 2007 Oct; 8(15):2579-92. PubMed ID: 17931092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
    Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
    Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.